文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

中国耐多药结核病患者贝达喹啉敏感性降低与临床结局的相关性

Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该回顾性队列研究纳入中国13个中心的277例接受贝达喹啉治疗的耐多药结核病患者,初始贝达喹啉耐药率为2.2%(6/277)。在94例获得连续分离株的病例中,11例出现贝达喹啉敏感性降低,其中6例检出Rv0678突变;获得性耐药者培养转阴失败风险更高。

要点

  • 中国MDR-TB患者初始贝达喹啉耐药率低,为2.2%(6/277)。
  • 治疗期间11/94例出现贝达喹啉敏感性降低,Rv0678突变占6/11。
  • 获得性贝达喹啉耐药者较初始耐药者治疗失败风险更高。

核心结论

  • 中国MDR-TB患者初始BDQ耐药率低,获得性BDQ耐药者治疗失败风险高于初始耐药者,Rv0678突变是本队列BDQ耐药的原因。

研究设计与样本

  • 回顾性队列研究,纳入中国13个中心的277例接受BDQ治疗的MDR-TB患者,排除治疗期间非结核分枝杆菌感染者。
  • 采用7H9 Middlebrook肉汤微量稀释法测定BDQ MIC,Sanger测序检测BDQ耐药相关突变。

主要发现

  • 277例MDR-TB患者中初始BDQ耐药比例为2.2%(6/277)。
  • 94例获得连续分离株的病例中,11例出现BDQ敏感性降低。
  • 5例获得性耐药病例中3例培养未转阴。
  • 11株BDQ耐药分离株中6株携带Rv0678突变,另3个BDQ耐药相关基因未检出突变。
  • 组间培养转阴时间无显著差异。

临床怎么用

  • 对接受BDQ治疗的MDR-TB患者,尤其是初始耐药者,应监测BDQ敏感性变化。
  • 获得性BDQ耐药与治疗失败风险相关,需关注培养转阴情况。

局限性

  • 15株因无法获得传代培养、30株因无连续分离株被排除最终分析。
  • 回顾性设计,样本来自13个中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to assess the proportion of multidrug-resistant tuberculosis (MDR-TB) cases with initial bedaquiline (BDQ) resistance, monitor the dynamics of BDQ susceptibility of Mycobacterium tuberculosis isolates during therapy, and correlate susceptibility with MDR-TB patient clinical outcomes in China. METHODS: A retrospective, cohort study of MDR-TB patients was conducted, with positive cultures collected from cases at 13 sites. Patients with nontuberculous mycobacterial infection during anti-TB therapy were excluded. BDQ minimal inhibitory concentrations (MICs) were determined using a 7H9 Middlebrook broth-based microdilution method. Mutations that conferred BDQ resistance were detected via Sanger sequencing. RESULTS: A total of 277 patients receiving BDQ treatment were studied, with BDQ resistance noted in isolates from 2.2% (6/277) of MDR-TB cases, sputum conversion observed in 5 cases, and culture conversion observed in 138 cases within 2 weeks. Another 15 and 30 isolates were excluded from final analysis due to failures in obtaining subcultures and serial isolates, respectively. Of 94 cases that yielded serial isolates, 11 exhibited reduced BDQ susceptibility, while 3 of 5 cases with acquired resistance failed to culture-convert. Sequence analysis revealed that 6 of 11 BDQ-resistant isolates harbored Rv0678 mutations; no mutations were detected in 3 other BDQ resistance-associated genes. No significant intergroup difference in culture conversion time was observed. CONCLUSIONS: MDR-TB patients in China exhibited a low initial BDQ resistance rate. MDR-TB cases with acquired BDQ resistance were at greater risk of treatment failure relative to initially BDQ-resistant cases. Rv0678 mutations accounted for BDQ resistance in this cohort.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Liu Y, Gao M, Du J, et al. Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China. Clin Infect Dis. 2021. PMID: 32667984. doi:10.1093/cid/ciaa1002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。